Listen to this page using ReadSpeaker
Archive for the FFB on the Road Category

ARVO 2015 Highlight: The National Eye Institute Invests $4 Million in Audacious-Goals Research

future of retinal researchThe National Eye Institute’s (NEI) establishment of its Audacious Goals in 2013 was a watershed moment in the drive to cure blinding retinal diseases. The mission of the program—to regenerate the neurons and neural connections in the eye and visual system—is synonymous with the Foundation’s mission to eradicate retinal diseases. Most important, it means that the NEI is making significant investments in research that will benefit people with retinal conditions, such as retinitis pigmentosa, Usher syndrome, Stargardt disease, and age-related macular degeneration.
Continue Reading…

ARVO 2015 Highlight: AMD Gene Therapy Performs Encouragingly in Human Study

an AMD eyeWhile treatments such as Lucentis®, Avastin®, and Eylea® have been saving and restoring vision for people with wet age-related macular degeneration (AMD) over the last several years, they have a significant drawback: The therapies require regular injections into the eye—in some cases, monthly—for the life of the patient.
Continue Reading…

ARVO 2015 Highlight: New Research Boosts Prospects for Saving Vision with RdCVF

Dr. SahelAn eye doctor could preserve meaningful vision in people with advanced retinitis pigmentosa (RP) by saving just five percent of their cones, the cells concentrated in the central retina enabling us to read, recognize colors and see in lighted conditions.
Continue Reading…

ARVO 2015 Highlight: A Cut-and-Paste Approach to Fixing Retinal-Disease Genes

gene editingI just returned from the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), the world’s largest eye-research conference, held this year in Denver. It attracted more than 11,000 scientists and physicians, including many of the 187 retinal researchers funded by the Foundation. The FFB science team and I worked feverishly to learn as much as possible about the latest news from the retinal-research front. It was truly exhilarating—albeit, at times, overwhelming.
Continue Reading…

VISIONS 2014 — Clinical Trials Need Pioneers

Drs. Shannon Boye and Jacque DuncanWith about 20 clinical trials underway for retinal degenerative diseases, and many more ready to launch soon, the buzz about signing up for them has never been louder. When it comes to human studies for potential treatments and cures, everybody wants in.
Continue Reading…

VISIONS 2014 – The Multi-Talented Dr. Shannon Boye

Shannon BoyeShannon Boye, Ph.D., is something of a rock star here at the VISIONS 2014 conference. Serving as a panelist in sessions on gene therapy and clinical trials, the University of Florida assistant professor has won compliments for her skill in explaining complicated research in plain English. And her compassion for those affected by retinal diseases is plain to see.
Continue Reading…

Colorado, VISIONS 2014 — See You There!

Colorado skylineIf you were someone affected by a retinal disease, and looking for the perfect event, one which combines the latest research updates with networking opportunities and support sessions, it would look exactly like the one FFB is hosting in Colorado June 19-22  — VISIONS 2014. Roughly 500 Foundation members, associates and researchers will gather at the annual conference, which will also be covered via this blog and social media, for those who can and can’t make it.
Continue Reading…

ARVO 2014: LCA Gene Therapy Recipient Featured During Keynote

Yannick Duwe and his father, Tony, at ARVOGene-therapy pioneer Jean Bennett, M.D., Ph.D., may have been the keynote speaker for the closing session at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), but Yannick Duwe, a 15-year-old patient with Leber congenital amaurosis (LCA) who was treated in her clinical trial six years ago, stole the show. He and his father, Tony, were part of a panel which also included members of Dr. Bennett’s research team.
Continue Reading…

ARVO 2014: Three Promising CEP290 Gene Therapy Alternatives

Renee Ryalls explains the dual-AAV gene therapy she's developing.While gene therapies for retinal degenerative diseases are making groundbreaking strides in both human and laboratory studies, the most widely and successfully used human-engineered virus for delivering replacement genes to retinal cells — the adeno-associated virus, or AAV — has one significant limitation. It can’t deliver relatively large genes, namely those larger than about 4.5 or 5 kilobases (kb). (Bases are the building blocks of a gene, and its size is expressed in kilobases.)
Continue Reading…

ARVO 2014: The Latest Retinal Research News from the Magic Kingdom

The Foundation’s science team is in Orlando over the next week for the annual meeting of the Association for Research in Vision in Ophthalmology, which convenes more than 10,000 of the world’s top eye researchers to report on their latest achievements.
Continue Reading…